Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases
Ramya Ramaswami(National Cancer Institute), Robert Yarchoan(National Cancer Institute), Kirsta Waldon(AIDS United), Kathryn Lurain(The Ohio State University), Seth M. Steinberg(National Institutes of Health), Denise Whitby(Frederick National Laboratory for Cancer Research), Ralph Mangusan(AIDS United), Thomas S. Uldrick(Regeneron (United States)), Richard F. Little(Dana-Farber Cancer Institute), Vickie Marshall(Leidos (United States)), Mark N. Polizzotto(AIDS United), Anaida Widell(AIDS United), Irene Ekwede(AIDS United), Elaine S. Jaffe(National Cancer Institute), Hao‐Wei Wang(Fu Jen Catholic University), Jomy George(National Institutes of Health), Stefania Pittaluga(New York University), Priscila Gonçalves(The Barbara Ann Karmanos Cancer Institute), Adam Rupert(Frederick National Laboratory for Cancer Research)
Cited by 78
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
|Blood|2011|2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k